Handelsavisen
prelaunch
03
0314.HK HKEX Drug Retailers

Sipai Health Technology Co, Ltd

HK$1,39
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Sipai Health Technology Co, Ltd operates in the drug retailing industry, providing pharmaceutical and healthcare products to consumers through its retail network.

Business. Sipai Health Technology Co, Ltd (0314.HK) is a drug retailer operating within the Food & Drug Retailing industry. The company is headquartered in China and is primarily listed on the Hong Kong Stock Exchange. It generates revenue through the product-sale model, focusing on the retail distribution of pharmaceutical and health-related products. Specific operating segments and geographic breakdowns are not disclosed in the available data.

Classification92 %
SectorConsumer Non-Cyclicals
Business sectorFood & Drug Retailing
IndustryDrug Retailers
ActivityFood & Drug Retailing
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 0314.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 0314.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Sipai Health Technology Co, Ltd (0314.HK) is a drug retailer operating within the Food & Drug Retailing industry. The company is headquartered in China and is primarily listed on the Hong Kong Stock Exchange. It generates revenue through the product-sale model, focusing on the retail distribution of pharmaceutical and health-related products. Specific operating segments and geographic breakdowns are not disclosed in the available data.

    Classification92 %
    SectorConsumer Non-Cyclicals
    Business sectorFood & Drug Retailing
    IndustryDrug Retailers
    ActivityFood & Drug Retailing
    AI synthesis
    GENERATED

    Sipai Health Technology Co, Ltd has a fully diluted share count of 735,798,314 shares, with no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities. The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

    The company reported a revenue of 4.71 billion CNY in the latest period, but it also reported a negative EPS of -0.40 CNY, indicating a loss per share. This loss per share suggests that the company is not currently generating profits, which is a concern for investors. The company's profitability metrics, such as net margin and return on equity, are not available, making it difficult to assess its financial performance relative to industry standards.

    Sipai Health Technology Co, Ltd's revenue is concentrated in a single business segment, as disclosed in its financial reports, with no geographic breakdown provided. This lack of geographic diversification could expose the company to regional economic or regulatory risks.

    The company's growth trajectory is uncertain, as there are no forward-looking revenue projections or outlooks provided in the available data. The absence of analyst estimates for future performance makes it difficult to assess the company's potential for growth or recovery.

    The company's risk profile is characterized by low dilution potential and an inability to assess liquidity risk due to missing balance-sheet data. The absence of going-concern language in source documents suggests that the company is not currently under immediate financial distress, but the lack of liquidity data is a red flag for investors.

    Recent events and filings do not provide additional insight into the company's operations or financial health. The absence of recent earnings calls, investor presentations, or regulatory filings beyond the basic financial snapshot limits the ability to assess the company's strategic direction or management commentary.

    Key takeaways
    • Sipai Health Technology Co, Ltd has no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities.
    • The company reported a negative EPS of -0.40 CNY, indicating a loss per share.
    • Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
    • Growth trajectory is uncertain due to the absence of forward-looking revenue projections.
    • Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Annual
    ANNUALFiled 2024-03-19
    FY 2024 · Full-year highlights

    Revenue ¥2.07B, −54,6% YoY; Operating income +64,6% YoY.

    Revenue¥2.07B−54,6 % YoY
    Operating income-¥126.7M+64,6 % YoY
    Net income-¥124.3M+61,6 % YoY
    Free cash flow-¥106.1M+67,2 % YoY
    EPS
    Operating cash flow¥6.4M+110,7 % YoY
    Financials
    Income statement
    Revenue¥2.07B
    Gross profit¥310.2M
    Operating income-¥126.7M
    Net income-¥124.3M
    Margins
    Gross margin15.0%
    Operating margin-6.1%
    Net margin-6.0%
    FCF margin-5.1%
    Balance sheet
    Total assets¥1.60B
    Total liabilities¥666.6M
    Total equity¥936.3M
    Cash & equivalents
    Long-term debt¥22.6M
    Cash flow
    Operating cash flow¥6.4M
    CapEx-¥6.2M
    Free cash flow-¥106.1M
    SBC
    P&L flow · revenue → net income
    Revenue ¥2.07BOperating costs ¥2.20BNet income ¥124.3M
    Highlights
    • Revenue ¥2.07B, −54,6% YoY
    • Operating income +64,6% YoY
    • Net income +61,6% YoY
    • Free cash flow +67,2% YoY
    • Net margin -6.0%

    Valuation FY

    Market price
    HK$1,39
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Sipai Health Technology Co, Ltd Market data — financials · 2026-05-26
    • Sipai Health Technology Co, Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    0314.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2024-03-19 17:45 UTCEARNINGSAnnual results — FY 2024 Revenue CNY 2.07B · Net CNY -124.3M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage